| Business Summary | | Novartis
AG
is
engaged
in
sales
and
in
innovation
in
its
core
businesses:
pharmaceuticals,
generics,
consumer
health,
eyecare
products
and
medicines,
and
animal
health.
The
Company
currently
operates
in
five
principal
industry
sectors:
Pharmaceuticals,
Generics,
Consumer
Health,
CIBA
Vision
and
Animal
Health.
Novartis
Pharmaceuticals
discovers,
develops,
manufactures
and
markets
prescription
medicines.
Novartis
Generics
provides
off-patent
pharmaceutical
products
and
substances.
Novartis
Consumer
Health
develops,
manufactures
and
markets
a
wide
range
of
health
and
medical
nutrition
products
and
a
portfolio
of
over-the-counter
self-medication
brands.
CIBA
Vision
is
engaged
in
the
research,
development
and
manufacturing
of
eye
care
products,
namely
soft
contact
lenses,
lens
care
products,
ophthalmic
pharmaceuticals
and
ophthalmic
surgical
products.
Novartis
Animal
Health
maintains
and
improves
the
health
and
well
being
of
companion
animals
and
farm
animals. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NVS
is
engaged
in
sales
and
product
innovation
in
the
areas
of
pharmaceuticals,
generics,
consumer
health,
eye
care
and
animal
health.
For
the
six
months
ended
6/01,
revenues
rose
11%
to
CHF15.46
billion.
Earnings
from
continuing
operations
according
to
US
GAAP
fell
22%
to
CHF2.58
billion.
Revenues
reflect
strength
in
pharmaceuticals,
including
Voltaren
and
Lamisil,
generics
and
consumer
health.
Earnings
refelct
higher
marketing
costs
and
a
CHF700M
in-process
US
GAAP
charge. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Daniel Vasella, 46 | Chairman,
CEO | Hans-Jorg Rudloff, 59 | Vice
Chairman | Helmut Sihler, 45 | Vice
Chairman | Raymond Breu, 54 | CFO | Ingrid Duplain, 55 | Sec.,
Director |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|